PhaseBio Pharmaceuticals announced the closing of $14.7 million in a financing mechanism called convertible notes that will help it advance…
Articles by Patrícia Silva, PhD
Scientists at Imperial College London have designed software that creates virtual 3-D versions of patients’ heart motion, helping doctors to…
SteadyMed Therapeutics recently reported its strategic goals and priorities for 2017, including plans to file a New Drug…
Vivus has acquired the global exclusive rights from Selten Pharma to develop and commercialize tacrolimus and ascomycin, two investigational treatments…
Eiger BioPharmaceuticals recently announced that a first patient has completed the 24-week dosing in the Phase 2 LIBERTY study assessing…
Arena Pharmaceuticals has completed enrolling patients with pulmonary arterial hypertension (PAH) in its Phase 2 clinical trial evaluating the effectiveness…
SteadyMed Therapeutics has named pulmonary hypertension (PH) advocate Carl Hicks Jr. to its newly created position of vice president for PH…
The U.S. Food and Drug Administration (FDA) has designed Reviva Pharmaceuticals’ RP5063 an Orphan Drug as a potential treatment of pulmonary…
ProMetic Life Sciences recently presented positive preclinical data on its fibrosis-targeting lead candidate, PBI-4050, showing that the drug…
The Fetal Health Foundation (FHF) awarded this year’s Brianna Marie Memorial Research Grant to Dr. Jan Deprest, a specialist…
Actelion announced that a Phase 2 clinical trial evaluating its pulmonary hypertension treatment, macitentan, in patients with inoperable chronic thromboembolic…
The Pulmonary Hypertension Association (PHA) is calling on people affected by pulmonary hypertension (PH) to attend the free…